Robert Best, CEO of MIMS Australia and New Zealand, discusses the changes implemented in February 2021 concerning Active Ingredient Prescribing which was introduced to achieve various objectives including the need to reduce the occurrence of accidental double dosing. He discusses some of the changes in the electronic prescribing systems and where the prescriber can discover more information should they require it.